The US Food and Drug Administration has approved the second CAR T-cell therapy, indicated for certain types of non-Hodgkin lymphoma. READ MORE

From The Journal

This paper explores the growing trend of clinical pathways for symptom management—including how they can be applied across cancer care and the positive downstream effects of pathways for symptom control—by examining the implementation of symptom management clinical pathways at one treatment center. READ MORE
October 15-18 marked the annual International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC). Oncologists from over 100 countries came together in Japan to discuss the latest developments and findings related to thoracic malignancy research. READ MORE
Journal of Clinical Pathways spoke with Dr Miller about a recent blog post, and how he sees future payment models adapting to an influx of costly new therapies as they enter the marker. READ MORE
New drugs for orphan and rare diseases have the potential to positively impact the lives of patients where historically few or no treatments had been available to manage the disease. READ MORE